Listing of Claims

1. (Previously presented) A compound of formula (I)



(I)

or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein:

R^0 is absent or C_1-C_6 alkylene;

R^1 is phenyl substituted by $-SO_yR^5$, (C_1-C_6 alkylene)-SO_yR^5, $-SO_yCF_3$, -(C_1-C_6 alkylene)-SO_yCF_3, -CO_2R^5, -(C_0-C_6 alkylene)-CO_2R^5, OCF_3, a five or six-membered aromatic heterocyclic group containing (i) from 1 to 4 nitrogen heteroatom(s) or (ii) 1 or 2 nitrogen heteroatom(s) and 1 oxygen or 1 sulphur heteroatom (said heterocyclic group being optionally substituted by halo, oxo, -CN, -COR^5, -CO_2R^5, -$CONR^5R^5$, -SO_yR^5, -SO_yCF_3, -$SO_2NR^5R^5$, -$NR^5SO_2R^5$, -OR^5, -OCF_3, -NR^5R^5, -(C_1-C_6 alkylene)-NR^5R^5, C_1-C_6 alkyl, fluoro(C_1-C_6)alkyl or C_3-C_7 cycloalkylor); or, when R^0 is C_1-C_6 alkylene, R^1 may also be a five or six-membered aromatic heterocyclic group containing (i) from 1 to 4 nitrogen heteroatom(s) or (ii) 1 or 2 nitrogen heteroatom(s) and 1 oxygen or 1 sulphur heteroatom or (iii) 1 or 2 oxygen or sulphur heteroatom(s), said heterocyclic group being optionally substituted by halo, oxo, -CN, -COR^5, -$CONR^5R^5$, -$SO_2NR^5R^5$, -$NR^5SO_2R^5$, -OR^5, -OR^{11}, -NR^5R^5, -(C_1-C_6 alkylene)-NR^5R^5, R^7 or R^{11}; said phenyl being optionally additionally substituted by halo, -CN, -COR^5, -$CONR^5R^5$, -$SO_2NR^5R^5$, -$NR^5SO_2R^5$, -OR^5, -NR^6R^5, -(C_1-C_6 alkylene)-NR^5R^5, C_1-C_6 alkyl, halo(C_1-C_6)alkyl or C_3-C_7 cycloalkyl;

R^2 is H, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, C_3-C_7 cycloalkyl, C_3-C_7 cycloalkenyl, phenyl, benzyl, R^8 or R^9, said C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl and benzyl being optionally substituted by halo, -OR^5, -OR^{10}, -CN, -CO_2R^7, -$OCONR^5R^6$, -$CONR^5R^6$, -$C(=NR^5)NR^5OR^5$, -$CONR^6NR^5R^5$, -NR^6R^6, -NR^5R^{10}, -NR^5COR^5, -NR^5COR^8, -NR^5COR^{10}, -$NR^5CO_2R^5$, -$NR^5CONR^5R^5$, -$SO_2NR^5R^5$, -$NR^5SO_2R^5$, -$NR^5SO_2NR^5R^5$, R^8 or R^9;

R^3 is H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl, benzyl, halo, -CN, -OR^7, -CO_2R^5, -$CONR^5R^5$, R^8 or R^9, said C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl and benzyl being optionally substituted by halo, -CN, -OR^5, -CO_2R^5, -$CONR^5R^5$, -$OCONR^5R^5$, -$NR^5CO_2R^5$, -NR^6R^6, -NR^5COR^5, -$SO_2NR^5R^5$, -$NR^5CONR^5R^5$, -$NR^5SO_2R^5$, R^8 or R^9;

R^4 is phenyl, naphthyl or pyridyl, each being optionally substituted by R^8, halo, -CN, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, -$CONR^5R^5$, OR^{11}, SO_xR^6, O-(C_1-C_6 alkylene)-$CONR^5R^5$, O-(C_1-C_6 alkylene)-NR^5R^5, or O-(C_1-C_6 alkylene)-OR^6;

each R^5 is independently either H, C_1-C_6 alkyl or C_3-C_7 cycloalkyl or, when two R^5 groups are attached to the same nitrogen atom, those two groups taken together with the nitrogen atom to which they are attached represent azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl or morpholinyl, said azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl and morpholinyl being optionally substituted by C_1-C_6 alkyl or C_3-C_7 cycloalkyl;

each R^6 is independently either H, C_1-C_6 alkyl or C_3-C_7 cycloalkyl;

R^7 is C_1-C_6 alkyl or C_3-C_7 cycloalkyl;

R^8 is a five or six-membered, aromatic heterocyclic group containing (i) from 1 to 4 nitrogen heteroatom(s) or (ii) 1 or 2 nitrogen heteroatom(s) and 1 oxygen or 1 sulphur heteroatom or (iii) 1 or 2 oxygen or sulphur heteroatom(s), said heterocyclic group being optionally substituted by halo, oxo, -CN, -COR^5, -$CONR^5R^5$, -$SO_2NR^5R^5$, -$NR^5SO_2R^5$, -OR^5, -NR^5R^5, -(C_1-C_6 alkylene)-NR^5R^5, C_1-C_6 alkyl, fluoro(C_1-C_6)alkyl or C_3-C_7 cycloalkyl;

R^9 is a four to seven-membered, saturated or partially unsaturated heterocyclic group containing (i) 1 or 2 nitrogen heteroatom(s) or (ii) 1 nitrogen heteroatom and 1 oxygen or 1 sulphur heteroatom or (iii) 1 oxygen or sulphur heteroatom, said heterocyclic group being optionally substituted by oxo, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, -SO_2R^5, -$CONR^5R^5$, -$COOR^5$, -CO-(C_1-C_6 alkylene)-OR^5 or -COR^5 and optionally substituted on a carbon atom which is not adjacent to a heteroatom by halo, -OR^5, -NR^6R^6, -NR^5COR^5, -NR^5COOR^5, -$NR^5CONR^5R^5$, -$NR^5SO_2R^5$ or -CN;

R^{10} is C_1-C_6 alkyl substituted by R^8, R^9, -OR^5, -$CONR^5R^5$, -NR^5COR^5 or -NR^5R^5;

R^{11} is phenyl optionally substituted by halo, -CN, -COR^5, -$CONR^5R^5$, -$SO_2NR^5R^5$, -$NR^5SO_2R^5$, -OR^5, -NR^5R^5, -(C_1-C_6 alkylene)-NR^5R^5, C_1-C_6 alkyl, halo(C_1-C_6)alkyl or C_3-C_7 cycloalkyl; and

x and y are independently 0, 1 or 2.

2. (Previously presented) A pharmaceutical composition comprising a compound according to claim 1 together with one or more pharmaceutically acceptable excipients, diluents or carriers.

3. (Previously presented) A pharmaceutical composition according to claim 2 comprising one or more additional therapeutic agents.

4–13. (Cancelled)

14. (Currently amended) A method of treating ~~an~~ HIV ~~or a genetically related retroviral infection,~~ or a resulting acquired immune deficiency syndrome (AIDS), comprising administering an effective amount of a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt[[,]] or solvate ~~or derivative~~ thereof, or a pharmaceutical composition according to claim 2.

15. (Currently amended) A method of treating ~~an~~ HIV ~~or a genetically related retroviral infection,~~ or a resulting acquired immune deficiency syndrome (AIDS), comprising administering an effective amount of a ~~compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, or a~~ pharmaceutical composition according to claim 3.

16. (Currently amended) A process for preparing the compound of formula (I)



(I)

or a pharmaceutically acceptable salt[[,]] or solvate ~~or pharmaceutically acceptable derivative~~ thereof, which comprises:

(A) reaction of a compound of formula (V)



(V)

with an alcohol of formula (IV),

R^1-OH (IV),

under conventional conditions; or

(B) reaction of an alcohol of formula (III)



(III)

with a compound of formula (II),

Lg-R^1 (II),

under conventional conditions; or

(C) reaction of a compound of formula (III) with an alcohol of formula (IV) under dehydrating conditions; or

(D) for the preparation of a compound of formula (I)



(I)

in which R^3 is halo, halogenating a compound of formula (X)



(X)

under conventional conditions[[;]].

~~(E) interconversion of a compound of formula (I) into another compound of formula (I); or~~

~~(F) deprotecting a protected derivative of compound of formula (I); and~~

~~optionally converting a compound of formula (I) prepared by any one of processes (A) to (F) into pharmaceutically acceptable salt, solvate or derivative thereof.~~

wherein:

each R^0 is absent or C_1-C_6 alkylene;

each R^1 is phenyl substituted by $-SO_xR^5$, (C_1-C_6 alkylene)-SO_xR^5, $-SO_xCF_3$, -(C_1-C_6 alkylene)-SO_xCF_3, $-CO_2R^5$, -(C_0-C_6 alkylene)-CO_2R^5, OCF_3, a five or six-membered aromatic heterocyclic group containing (i) from 1 to 4 nitrogen heteroatom(s) or (ii) 1 or 2 nitrogen heteroatom(s) and 1 oxygen or 1 sulphur heteroatom (said heterocyclic group being optionally substituted by halo, oxo, -CN, $-COR^5$, $-CO_2R^5$, $-CONR^5R^5$, $-SO_3R^5$, $-SO_xCF_3$, $-SO_2NR^5R^5$, $-NR^5SO_2R^5$, $-OR^5$, $-OCF_3$, $-NR^5R^5$, -(C_1-C_6 alkylene)-NR^5R^5, C_1-C_6 alkyl, fluoro(C_1-C_6)alkyl or C_3-C_7 cycloalkylor); or, when R^0 is C_1-C_6 alkylene, R^1 may also be a five or six-membered aromatic heterocyclic group containing (i) from 1 to 4 nitrogen heteroatom(s) or (ii) 1 or 2 nitrogen heteroatom(s) and 1 oxygen or 1 sulphur heteroatom or (iii) 1 or 2 oxygen or sulphur heteroatom(s), said heterocyclic group being optionally substituted by halo, oxo, -CN, $-COR^5$, $-CONR^5R^5$, $-SO_2NR^5R^5$, $-NR^5SO_2R^5$, $-OR^5$, $-OR^{11}$, $-NR^5R^5$, -(C_1-C_6 alkylene)-NR^5R^5, R^7 or R^{11}; said phenyl being optionally additionally substituted by halo, -CN, $-COR^5$, $-CONR^5R^5$, $-SO_2NR^5R^5$, $-NR^5SO_2R^5$, $-OR^5$, $-NR^5R^5$, -(C_1-C_6 alkylene)-NR^5R^5, C_1-C_6 alkyl, halo(C_1-C_6)alkyl or C_3-C_7 cycloalkyl;

each R^2 is H, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, C_3-C_7 cycloalkyl, C_3-C_7 cycloalkenyl, phenyl, benzyl, R^8 or R^9, said C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl and benzyl being optionally substituted by halo, -OR^5, -OR^{10}, -CN, -CO_2R^7, -$OCONR^5R^5$, -$CONR^5R^5$, -$C(=NR^5)NR^5OR^5$, -$CONR^5NR^5R^5$, -NR^6R^6, -NR^5R^{10}, -NR^5COR^5, -NR^5COR^8, -NR^5COR^{10}, -$NR^5CO_2R^5$, -$NR^5CONR^5R^5$, -$SO_2NR^5R^5$, -$NR^5SO_2R^5$, -$NR^5SO_2NR^5R^5$, R^8 or R^9;

each R^3 is H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl, benzyl, halo, -CN, -OR^7, -CO_2R^5, -$CONR^5R^5$, R^8 or R^9, said C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl and benzyl being optionally substituted by halo, -CN, -OR^5, -CO_2R^5, -$CONR^5R^5$, -$OCONR^5R^5$, -$NR^5CO_2R^5$, -NR^6R^6, -NR^5COR^5, -$SO_2NR^5R^5$, -$NR^5CONR^5R^5$, -$NR^5SO_2R^5$, R^8 or R^9;

each R^4 is phenyl, naphthyl or pyridyl, each being optionally substituted by R^8, halo, -CN, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, -$CONR^5R^5$, OR^{11}, SO_2R^6, O-(C_1-C_6 alkylene)-$CONR^5R^5$, O-(C_1-C_6 alkylene)-NR^5R^5, or O-(C_1-C_6 alkylene)-OR^6;

each R^5 is independently either H, C_1-C_6 alkyl or C_3-C_7 cycloalkyl or, when two R^5 groups are attached to the same nitrogen atom, those two groups taken together with the nitrogen atom to which they are attached represent azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl or morpholinyl, said azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl and morpholinyl being optionally substituted by C_1-C_6 alkyl or C_3-C_7 cycloalkyl;

each R^6 is independently either H, C_1-C_6 alkyl or C_3-C_7 cycloalkyl;

each R^7 is C_1-C_6 alkyl or C_3-C_7 cycloalkyl;

each R^8 is a five or six-membered, aromatic heterocyclic group containing (i) from 1 to 4 nitrogen heteroatom(s) or (ii) 1 or 2 nitrogen heteroatom(s) and 1 oxygen or 1 sulphur heteroatom or (iii) 1 or 2 oxygen or sulphur heteroatom(s), said heterocyclic group being optionally substituted by halo, oxo, -CN, -COR^5, -$CONR^5R^5$, -$SO_2NR^5R^5$, -$NR^5SO_2R^5$, -OR^5, -NR^5R^5, -(C_1-C_6 alkylene)-NR^5R^5, C_1-C_6 alkyl, fluoro(C_1-C_6)alkyl or C_3-C_7 cycloalkyl;

each R^9 is a four to seven-membered, saturated or partially unsaturated heterocyclic group containing (i) 1 or 2 nitrogen heteroatom(s) or (ii) 1 nitrogen heteroatom and 1 oxygen or 1 sulphur heteroatom or (iii) 1 oxygen or sulphur heteroatom, said heterocyclic group being optionally

substituted by oxo, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, $-SO_2R^5$, $-CONR^5R^5$, $-COOR^5$, $-CO-(C_1$-C_6 alkylene)-OR^5 or $-COR^5$ and optionally substituted on a carbon atom which is not adjacent to a heteroatom by halo, $-OR^5$, $-NR^5R^5$, $-NR^5COR^5$, $-NR^5COOR^5$, $-NR^5CONR^5R^5$, $-NR^5SO_2R^5$ or -CN;

each R^{10} is C_1-C_6 alkyl substituted by R^8, R^9, $-OR^5$, $-CONR^5R^5$, $-NR^5COR^5$ or $-NR^5R^5$;

each R^{11} is phenyl optionally substituted by halo, -CN, $-COR^5$, $-CONR^5R^5$, $-SO_2NR^5R^5$, $-NR^5SO_2R^5$, $-OR^5$, $-NR^5R^5$, $-(C_1$-C_6 alkylene)-NR^5R^5, C_1-C_6 alkyl, halo(C_1-C_6)alkyl or C_3-C_7 cycloalkyl;

x and y are independently 0, 1 or 2;

Lg is sulphonyl chloride; and

Lg^2 is a sulphonic ester group.

17. (Cancelled)